Kymera Therapeutics (KYMR) Other Accumulated Expenses (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Other Accumulated Expenses data on file, last reported at $24.4 million in Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 73.27% year-over-year to $24.4 million in Q1 2026; TTM through Mar 2026 was $24.4 million, a 73.27% increase from a year earlier, with the FY2025 full-year figure at $21.4 million, up 9474.44% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $24.4 million, up from $21.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for KYMR reached as high as $24.4 million in Q1 2026 and fell as low as $117000.0 in Q2 2025.
• Historically, Other Accumulated Expenses has averaged $5.9 million across 5 years, with a median of $824000.0 in 2024.
• On a YoY basis, Other Accumulated Expenses climbed as much as 89727.78% in 2022 and fell as far as 97.32% in 2022.
• Year by year, Other Accumulated Expenses stood at $407000.0 in 2022, then increased by 28.75% to $524000.0 in 2023, then plunged by 57.44% to $223000.0 in 2024, then soared by 9474.44% to $21.4 million in 2025, then grew by 14.16% to $24.4 million in 2026.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $24.4 million in Q1 2026, $21.4 million in Q4 2025, and $267000.0 in Q3 2025.